Skip to main content
Premium Trial:

Request an Annual Quote

Waters Q2 Revenues up 31 Percent

NEW YORK – Waters reported on Tuesday that its second quarter revenues were up 31 percent year over year.

For the three months ended June 29, the company posted revenues of $681.6 million, up 31 percent from $520.0 million in Q2 2020, and above the average Wall Street estimate of $621.5 million. Organic revenues grew 27 percent, with foreign currency translation boosting revenues by 4 percent, the company said.

By end market, pharma sales were up 34 percent to $416.7 from $311.0 million; government and academic sales rose 10 percent to $62.4 million from $56.9 million; and industrial sales rose 33 percent to $202.6 million from $152.1 million.

Waters' recurring revenues, which include its services and consumables businesses, rose 22 percent during the quarter to $367.2 million from $300.2 million, while instrument sales were up 43 percent to $314.5 million from $219.8 million.

Waters CEO Udit Batra said in a statement accompanying release of the Q2 earnings that the results "were led by strong growth in our pharma and industrial end markets … with total sales increasing across every region."

Waters' Q2 net income was $167.3 million, or $2.69 per share, compared to $123.0 million, or $1.98 per share, a year ago. On a non-GAAP basis, the company reported EPS of $2.60, beating analysts' average estimate of $2.24.

Water's R&D spending in Q2 was up 44 percent to $44.9 million from $31.2 million a year ago, while SG&A costs rose 35 percent to $158.2 million from $117.4 million.

The company ended the quarter with $663.6 million in cash, cash equivalents, and investments.

In Tuesday morning trading on the New York Stock Exchange, shares of Waters were down 3 percent to $377.05.

The Scan

Nucleotide Base Detected on Near-Earth Asteroid

Among other intriguing compounds, researchers find the nucleotide uracil, a component of RNA sequences, in samples collected from the near-Earth asteroid Ryugu, as they report in Nature Communications.

Clinical Trial Participants, Investigators Point to Importance of Clinical Trial Results Reporting in Canadian Study

Public reporting on clinical trial results is crucial, according to qualitative interviews with clinical trial participants, investigators, and organizers from three provinces appearing in BMJ Open.

Old Order Amish Analysis Highlights Autozygosity, Potential Ties to Blood Measures

Researchers in BMC Genomics see larger and more frequent runs-of-homozygosity in Old Order Amish participants, though only regional autozygosity coincided with two blood-based measures.

Suicidal Ideation-Linked Loci Identified Using Million Veteran Program Data

Researchers in PLOS Genetics identify risk variants within and across ancestry groups with a genome-wide association study involving veterans with or without a history of suicidal ideation.